Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis

被引：17

作者：

Delgado, J. ^{[1
]}

Pillai, S. ^{[2
]}

Phillips, N. ^{[2
]}

Brunet, S. ^{[1
]}

Pratt, G. ^{[2
]}

Briones, J. ^{[1
]}

Lovell, R. ^{[2
]}

Martino, R. ^{[1
]}

Ewing, J. ^{[2
]}

Sureda, A. ^{[1
]}

Milligan, D. W. ^{[2
]}

Sierra, J. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Serv Hematol Clin, Dept Haematol, Barcelona 08025, Spain

[2] Heart England Natl Hlth Serv Trust, Dept Haematol, Birmingham, W Midlands, England

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷 / 12期

关键词：

allogeneic HCT; case control study; chronic lymphocytic leukaemia; STEM-CELL TRANSPLANTATION; CLINICAL-EFFICACY; ALEMTUZUMAB; FLUDARABINE; THERAPY; CYCLOPHOSPHAMIDE; DISEASE;

D O I：

10.1093/annonc/mdp259

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients and methods: Cases comprised 37 patients who underwent RIC allo-HCT. Haemopoietic cell grafts were harvested from HLA-matched siblings (27) and unrelated donors (7). Controls consisted of 43 patients from the same institutions who received conventional therapy only. Matching variables were age at diagnosis and time to first CLL-specific therapy. Results: Both patient groups were well balanced in terms of cytogenetics by FISH, CD38 and ZAP-70 expression, and immunoglobulin heavy-chain variable region mutational status. Median overall survival was 113 months for HCT patients and 85 months for controls when calculated from time of diagnosis (P = 0.072) and 103 and 67 months, respectively, when calculated from time of first therapy (P = 0.041). Conclusion: RIC allo-HCT is a reasonable option for patients with high-risk CLL. However, these results require confirmation before the procedure can be recommended outside clinical trials.

引用

页码：2007 / 2012

页数：6

共 20 条

[1] Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

T Kim, Haesook ;

Li, Shuli ;

Stephans, Katherine ;

Fisher, David C. ;

Cutler, Corey ;

Ho, Vincent ;

Lee, Stephanie J. ;

Milford, Edgar L. ;

Ritz, Jerome ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Gribben, John G. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) :1056-1064

[2] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].

Byrd, John C. ;

Lin, Thomas S. ;

Dalton, James T. ;

Wu, Di ;

Phelps, Mitch A. ;

Fischer, Beth ;

Moran, Mollie ;

Blum, Kristie A. ;

Rovin, Brad ;

Brooker-McEldowney, Michelle ;

Broering, Sarah ;

Schaaf, Larry J. ;

Johnson, Amy J. ;

Lucas, David M. ;

Heerema, Nyla A. ;

Lozanski, Gerard ;

Young, Donn C. ;

Suarez, Jose-Ramon ;

Colevas, A. Dimitrios ;

Grever, Michael R. .

BLOOD, 2007, 109 (02) :399-404

[3] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[4] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

[5] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].

Cheson, BD ;

Bennett, JM ;

Grever, M ;

Kay, N ;

Keating, MJ ;

OBrien, S ;

Rai, KR .

BLOOD, 1996, 87 (12) :4990-4997

[6] Mechanisms of disease: Chronic lymphocytic leukemia [J].

Chiorazzi, N ;

Rai, KR ;

Ferrarini, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :804-815

[7] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study [J].

Coiffier, Bertrand ;

Lepretre, Stephane ;

Pedersen, Lars Moller ;

Gadeberg, Ole ;

Fredriksen, Henrik ;

van Oers, Marinus H. J. ;

Wooldridge, James ;

Kloczko, Janusz ;

Holowiecki, Jerzy ;

Hellmann, Anrzej ;

Walewski, Jan ;

Flensburg, Mimi ;

Petersen, Jorgen ;

Robak, Tadeusz .

BLOOD, 2008, 111 (03) :1094-1100

[8] Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study [J].

Delgado, J ;

Thomson, K ;

Russell, N ;

Ewing, J ;

Stewart, W ;

Cook, G ;

Devereux, S ;

Lovell, R ;

Chopra, R ;

Marks, DI ;

Mackinnon, S ;

Milligan, DW .

BLOOD, 2006, 107 (04) :1724-1730

[9] The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia [J].

Delgado, Julio ;

Pillai, Srinivas ;

Benjamin, Reuben ;

Caballero, Dolores ;

Martino, Rodrigo ;

Nathwani, Amit ;

Lovell, Richard ;

Thomson, Kirsty ;

Perez-Simon, Jose A. ;

Sureda, Anna ;

Kottaridis, Panagiotis ;

Vazquez, Lourdes ;

Peggs, Karl ;

Sierra, Jorge ;

Milligan, Donald ;

Mackinnon, Stephen .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1288-1297

[10] Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study [J].

Dispenzieri, A ;

Kyle, RA ;

Lacy, MQ ;

Therneau, TM ;

Larson, DR ;

Plevak, MF ;

Rajkumar, SV ;

Fonseca, R ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Zeldenrust, SR ;

Snow, DS ;

Hayman, SR ;

Litzow, MR ;

Gastineau, DA ;

Tefferi, A ;

Inwards, DJ ;

Micallef, IN ;

Ansell, SM ;

Porrata, LF ;

Elliott, MA ;

Gertz, MA .

BLOOD, 2004, 103 (10) :3960-3963

← 1 2 →